Anzeige
Meldung des Tages: Early Bird Special: Ad-hoc im Schatten einer milliardenschweren Entscheidung

Tyra Biosciences News

Aktie
WKN:  ISIN:  US90240B1061 US-Symbol:  TYRA Branche:  Biotechnologie Land:  USA
34,01 $
-0,74 $
-2,13%
29,017 € 01.05.26
Depot/Watchlist
Marktkapitalisierung *
1,12 Mrd. €
Streubesitz
-
KGV
-9,46
Index-Zuordnung
-

Tyra Biosciences News

17.04.26 - PR Newswire
Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors
Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors PR Newswire
02.03.26 - PR Newswire
Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights
Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights PR Newswire
23.02.26 - PR Newswire
Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium
Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium PR Newswire
19.02.26 - PR Newswire
Tyra Biosciences to Participate in Upcoming Investor Conferences
Tyra Biosciences to Participate in Upcoming Investor Conferences PR Newswire
01.12.25 - PR Newswire
Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer
Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer PR Newswire
12.11.25 - PR Newswire
Tyra Biosciences Announces Participation at Upcoming Investor Events
Tyra Biosciences Announces Participation at Upcoming Investor Events PR Newswire
05.11.25 - PR Newswire
Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights
Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights PR Newswire
21.08.25 - PR Newswire
Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia
Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia PR Newswire
20.08.25 - PR Newswire
Tyra Biosciences Announces Participation at Upcoming Investor Events
Tyra Biosciences Announces Participation at Upcoming Investor Events PR Newswire
14.08.25 - PR Newswire
Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights
Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights PR Newswire
08.07.25 - PR Newswire
Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025
Tyra Biosciences Announces Late-​Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025 PR Newswire
30.06.25 - PR Newswire
Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)
Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-​Muscle Invasive Bladder Cancer (SURF302) PR Newswire
12.05.25 - PR Newswire
Tyra Biosciences to Participate at Upcoming Investor Conferences
Tyra Biosciences to Participate at Upcoming Investor Conferences PR Newswire
08.05.25 - PR Newswire
Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights
Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights PR Newswire

Newssuche

Videos

newspaper
26.04.26
Big Fish Strategy Einführung
Strategie-​Paket inklusive Live-​Webinar am 3.5., Videoaufzeichnung, Unterlagen und Nachbetreuung JETZT ... Mehr »
Anzeige

Aktie im Fokus

Mit Graphen gegen jede Abwehr
Plaid Technologies
0,396 €
+7,03%
Plaid Technologies Chart
Die Zukunft der Drohnen ist da
Mehr zur Aktie »